Clinical trial
Proxalutamide Treatment for Hospitalized COVID-19 Patients
NCT04728802 is registered in ClinicalTrials.gov with Applied Biology, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Proxalutamide Treatment for Hospitalized COVID-19 Patients
- Lead sponsor
- Applied Biology, Inc.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- February 1, 2021
- Completion date
- April 15, 2021
- Enrollment
- 645 (actual)
- Sites
- 8
Conditions
As the registry lists them; a condition with its own page is linked.
covid19, sars (severe acute respiratory syndrome)